What Biotech Actually Is

Defining Biotech

"Biotechnology" gets used so loosely that it sometimes means nothing in particular. A useful working definition: the deliberate use of living systems or their components to make products or solve problems.

That definition is broad on purpose. It includes:

• Engineered bacteria producing insulin
• Yeast brewing beer
• CRISPR-edited crops
• Monoclonal antibody cancer drugs
• Lab-grown meat
• Bioplastics
• Bioremediation of oil spills
• Recombinant vaccines
• Forensic DNA analysis
• Synthetic biology designing entirely new organisms

By that definition, biotech is older than civilization — humans have been using yeast for brewing and bread for at least 9,000 years, and selective breeding of crops and livestock for longer than that. What changed in the 20th century is that we acquired the ability to manipulate biology at the molecular level. The biology stayed the same. The precision and speed didn't.

Practitioners usually divide biotech into "colors" based on application:

• Red biotech — Medical and pharmaceutical applications (drugs, vaccines, gene therapy)
• Green biotech — Agricultural applications (crops, livestock, food)
• White biotech — Industrial applications (enzymes, biofuels, materials)
• Blue biotech — Marine and aquatic applications (covered in the Marine Bio track)
• Yellow biotech — Food biotech specifically (fermentation, food engineering)
• Gray biotech — Environmental applications (bioremediation, waste treatment)

These categories blur in practice. A microbial strain engineered to produce a pharmaceutical compound is red biotech using white biotech methods. The colors are a useful heuristic, not a strict taxonomy.

The Three Foundational Discoveries

Modern biotech rests on three foundational scientific advances. Each one happened within a few decades of the others, and together they made everything that followed possible.

The structure of DNA (1953). Watson, Crick, and (uncredited at the time) Rosalind Franklin's contributions established that genetic information is stored in a double helix of nucleotides. Foundations F1 covered the central dogma — DNA to RNA to protein — that emerged from this discovery. Until DNA's structure was known, biology was largely a descriptive science. After 1953, it became a chemical one. The full implications took decades to unfold.

Recombinant DNA technology (1973). Stanley Cohen and Herbert Boyer figured out how to cut DNA from one organism, splice it into a plasmid (a small circular DNA molecule from bacteria), and insert that plasmid into a different organism. The result: bacteria that contained — and could express — genes from other species. Suddenly, the boundary between species, evolutionarily separate for billions of years, became permeable to deliberate human engineering. Boyer co-founded Genentech in 1976. This single technology made the biotech industry possible.

Polymerase Chain Reaction (1983). Kary Mullis invented a technique for making millions of copies of a specific DNA sequence in a test tube. PCR turned DNA into a substance you could practically work with — manipulate, sequence, modify, detect. Before PCR, working with specific DNA fragments was painfully slow. After PCR, it was almost instantaneous. Mullis won the 1993 Nobel Prize. Every modern diagnostic, every COVID test, every CRISPR experiment uses PCR at some stage.

These three discoveries — DNA structure, recombinant DNA, and PCR — are the bedrock. Everything in modern biotech is, in some sense, an application or extension of one of them. Subsequent advances (sequencing, CRISPR, synthetic biology) build on this foundation rather than replacing it.

The Birth of an Industry

The transition from biology as a research field to biotech as an industry happened in a remarkably specific window — roughly 1976 to 1986. The key events:

1976 — Genentech founded. Boyer and venture capitalist Robert Swanson co-found Genentech with a specific business plan: use recombinant DNA technology to produce human pharmaceuticals. Their first goal was to make human insulin in bacteria. At the time, most insulin was extracted from cow and pig pancreases — a process limited by animal supply and prone to allergic reactions.

1978 — Human insulin produced. Genentech successfully produces functional human insulin from genetically engineered E. coli. The bacteria contain the human insulin gene; they read it; they produce human insulin protein. It's the first time a human protein has been produced by another organism through genetic engineering.

1980 — Genentech IPO. The IPO described in the hook. Establishes that recombinant DNA technology is investable, fundable, and commercially significant.

1982 — Humulin approved. Recombinant human insulin (Humulin), produced by Genentech and marketed by Eli Lilly, becomes the first FDA-approved drug made through recombinant DNA technology. The era of biopharmaceuticals begins.

1980 — Diamond v. Chakrabarty. Supreme Court rules that genetically engineered organisms can be patented. The case involved a bacterium engineered to break down oil spills. The decision establishes the intellectual property framework for the biotech industry — engineered organisms aren't just discoveries, they're inventions.

1980 — Bayh-Dole Act. Allows universities and small businesses to retain patent rights to inventions made with federal funding. Creates the legal framework for academic-industry technology transfer that defines modern biotech.

This ten-year window created the legal, financial, regulatory, and scientific infrastructure that the rest of the industry has been operating within ever since. The biotech industry is, in important ways, still living in 1986.

The Modern Biotech Landscape

Scale. The global biotech industry generates over $700 billion in annual revenue. In the United States alone, it directly employs over 2 million people. The top biotech companies (Moderna, Regeneron, Vertex, Illumina) each carry multi-tens-of-billions market capitalizations.

Geographic concentration. US biotech is geographically clustered to an extreme degree. The major hubs are Boston/Cambridge (anchored by MIT, Harvard, and Massachusetts General Hospital), the San Francisco Bay Area (UCSF, Stanford, and the original Genentech), San Diego (UCSD, Salk Institute, Scripps), Research Triangle Park in North Carolina, and Washington DC/Maryland (NIH-adjacent).

Industry structure. The industry is bifurcated. Big Pharma — Pfizer, Roche, Novartis, Johnson & Johnson, Merck — has acquired most successful biotech companies. Small biotech startups continue to do most early-stage innovation, often spinning out of academic labs. Mid-sized biotech (Moderna, Regeneron, Vertex) occupies a difficult middle ground.

Funding patterns. Bringing a single drug to market costs an average of $1–2 billion and takes 10–15 years. Most companies don't make money for many years. Funding comes from venture capital, government grants (especially NIH), partnerships with Big Pharma, and public market investors. The result is a famously cyclical industry.

International landscape. US biotech is dominant but not alone. Switzerland, the UK, Germany, and Denmark host major industries. China is now the second-largest market globally. Singapore, South Korea, and Japan have specialized strengths. The industry is increasingly global.

Wait, Actually…

The first genetically engineered organism wasn't a pharmaceutical bacterium or a CRISPR crop. It was a chimeric monkey kidney virus — produced by Paul Berg at Stanford in 1972, the year before Cohen and Boyer's famous recombinant DNA experiments.

Berg combined DNA from a monkey virus called SV40 with DNA from a bacterial virus called lambda phage. But Berg never inserted it into a living cell. The reason: SV40 was known to cause tumors in some animals. Berg paused his own work voluntarily and called for the Asilomar Conference (1975) to establish safety guidelines. That conference produced the foundational biosafety framework still in use today.

Berg won the 1980 Nobel Prize in Chemistry, partly for the recombinant DNA work and partly for catalyzing the responsible development of biotechnology. His decision to pause work he could have pursued is one of the more remarkable cases of a scientist exercising restraint with technology he himself invented.

The biotech industry was founded by people who had already grappled, deeply, with the safety implications of what they were building. That doesn't mean current biotech is fully safe. It does mean the field has a longer tradition of self-reflection about risk than most industries.

---